Intellia Therapeutics, Inc.
NTLANasdaqCIK 1652130HealthcareFiscal year ends Dec 31
Reports and events: 206 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-0820:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-385194 |
| 2026-09-0420:06 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-383645 |
| 2026-08-0620:05 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-337952 |
| 2026-08-0611:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-336772 |
| 2026-06-1512:52 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-270358 |
| 2026-06-1020:36 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-265934 |
| 2026-05-1111:49 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-215740 |
| 2026-05-1111:36 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-215721 |
| 2026-04-3020:30 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-197489 |
| 2026-04-3020:10 ET | DEF 14A | Proxy statementPeriod 2026-06-09 | 0001193125-26-197283 |
| 2026-04-2713:13 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-179401 |
| 2026-04-1020:16 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-151300 |
| 2026-03-0213:16 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-084309 |
| 2026-02-2621:06 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-076550 |
| 2026-02-2612:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-073456 |
| 2026-01-2713:19 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-023387 |
| 2026-01-0913:07 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-008307 |
| 2025-11-1022:24 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-274596 |
| 2025-11-0621:26 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-269680 |
| 2025-11-0621:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-269479 |
| 2025-10-2920:22 ET | 8-K | 8.01 Other events | 0001193125-25-256378 |
| 2025-10-2712:01 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-250757 |
| 2025-09-2520:19 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-217484 |
| 2025-08-0720:06 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-104987 |
| 2025-08-0711:45 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-104574 |
| 2025-06-1611:00 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-141087 |
| 2025-06-1220:31 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-25-085479 |
| 2025-05-2820:38 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events | 0001193125-25-129524 |
| 2025-05-1910:21 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-122076 |
| 2025-05-0820:05 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-066914 |
| 2025-05-0811:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-066403 |
| 2025-04-3020:04 ET | DEF 14A | Proxy statementPeriod 2025-06-11 | 0000950170-25-061023 |
| 2025-04-0710:05 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-25-073904 |
| 2025-02-2721:03 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-029007 |
| 2025-02-2712:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-028373 |
| 2025-02-2121:06 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-25-031989 |
| 2025-01-1012:30 ET | 8-K | 2.02 Results of operations; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-004080 |
| 2024-11-1812:00 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-260417 |
| 2024-11-0721:05 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-123276 |
| 2024-11-0712:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122810 |
| 2024-10-2520:59 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-244201 |
| 2024-08-0820:06 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-093907 |
| 2024-08-0811:45 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093339 |
| 2024-06-2612:06 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-168545 |
| 2024-06-1420:24 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-073709 |
| 2024-06-1320:59 ET | 8-K | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000950170-24-073116 |
| 2024-05-0920:25 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-057046 |
| 2024-05-0911:40 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-056286 |
| 2024-04-2920:16 ET | DEF 14A | Proxy statementPeriod 2024-06-12 | 0000950170-24-049875 |
| 2024-04-1520:21 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0000950170-24-044424 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.